Effect of melittin on metabolomic profile and cytokine production in PMA-differentiated THP-1 cells

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Melittin, the major active peptide of honeybee venom (BV), has potential for use in adjuvant immunotherapy. The immune system response to different stimuli depends on the secretion of different metabolites from macrophages. One potent stimulus is lipopolysaccharide (LPS), a component isolated from gram-negative bacteria, which induces the secretion of pro-inflammatory cytokines in macrophage cell cultures. This secretion is amplified when LPS is combined with melittin. In the present study, pure melittin was isolated from whole BV by flash chromatography to obtain pure melittin. The ability of melittin to enhance the release of tumour necrosis factor-α (TNF-α), Interleukin (IL-1β, IL-6, and IL-10) cytokines from a macrophage cell line (THP-1) was then assessed. The response to melittin and LPS, applied alone or in combination, was characterised by metabolic profiling, and the metabolomics results were used to evaluate the potential of melittin as an immune adjuvant therapy. The addition of melittin enhanced the release of inflammatory cytokines induced by LPS. Effective chromatographic separation of metabolites was obtained by liquid chromatography-mass spectrometry (LC-MS) using a ZIC-pHILIC column and an ACE C4 column. The levels of 108 polar and non-polar metabolites were significantly changed (p ˂ 0.05) following cell activation by the combination of LPS and melittin when compared to untreated control cells. Overall, the findings of this study suggested that melittin might have a potential application as a vaccine adjuvant.

LanguageEnglish
Article number72
Number of pages21
JournalVaccines
Volume6
Issue number4
DOIs
Publication statusPublished - 13 Oct 2018

Fingerprint

Melitten
Metabolomics
Cytokines
Lipopolysaccharides
Macrophages
Venoms
Gram-Negative Bacteria
Interleukin-1beta
Liquid Chromatography
Interleukin-10
Immunotherapy
Chromatography
Immune System
Interleukin-6
Mass Spectrometry
Vaccines
Cell Culture Techniques
Tumor Necrosis Factor-alpha

Keywords

  • adjuvant vaccine
  • LPS stimulation
  • macrophages
  • melittin
  • PMA differentiated
  • pro- and anti-inflammatory cytokines
  • THP-1 cells

Cite this

@article{a348b8a13074401ebddca7645e08aa2a,
title = "Effect of melittin on metabolomic profile and cytokine production in PMA-differentiated THP-1 cells",
abstract = "Melittin, the major active peptide of honeybee venom (BV), has potential for use in adjuvant immunotherapy. The immune system response to different stimuli depends on the secretion of different metabolites from macrophages. One potent stimulus is lipopolysaccharide (LPS), a component isolated from gram-negative bacteria, which induces the secretion of pro-inflammatory cytokines in macrophage cell cultures. This secretion is amplified when LPS is combined with melittin. In the present study, pure melittin was isolated from whole BV by flash chromatography to obtain pure melittin. The ability of melittin to enhance the release of tumour necrosis factor-α (TNF-α), Interleukin (IL-1β, IL-6, and IL-10) cytokines from a macrophage cell line (THP-1) was then assessed. The response to melittin and LPS, applied alone or in combination, was characterised by metabolic profiling, and the metabolomics results were used to evaluate the potential of melittin as an immune adjuvant therapy. The addition of melittin enhanced the release of inflammatory cytokines induced by LPS. Effective chromatographic separation of metabolites was obtained by liquid chromatography-mass spectrometry (LC-MS) using a ZIC-pHILIC column and an ACE C4 column. The levels of 108 polar and non-polar metabolites were significantly changed (p ˂ 0.05) following cell activation by the combination of LPS and melittin when compared to untreated control cells. Overall, the findings of this study suggested that melittin might have a potential application as a vaccine adjuvant.",
keywords = "adjuvant vaccine, LPS stimulation, macrophages, melittin, PMA differentiated, pro- and anti-inflammatory cytokines, THP-1 cells",
author = "Alqarni, {Abdulmalik M.} and Ferro, {Valerie A.} and Parkinson, {John A.} and Dufton, {Mark J.} and Watson, {David G.}",
year = "2018",
month = "10",
day = "13",
doi = "10.3390/vaccines6040072",
language = "English",
volume = "6",
journal = "Vaccines",
issn = "2076-393X",
number = "4",

}

TY - JOUR

T1 - Effect of melittin on metabolomic profile and cytokine production in PMA-differentiated THP-1 cells

AU - Alqarni, Abdulmalik M.

AU - Ferro, Valerie A.

AU - Parkinson, John A.

AU - Dufton, Mark J.

AU - Watson, David G.

PY - 2018/10/13

Y1 - 2018/10/13

N2 - Melittin, the major active peptide of honeybee venom (BV), has potential for use in adjuvant immunotherapy. The immune system response to different stimuli depends on the secretion of different metabolites from macrophages. One potent stimulus is lipopolysaccharide (LPS), a component isolated from gram-negative bacteria, which induces the secretion of pro-inflammatory cytokines in macrophage cell cultures. This secretion is amplified when LPS is combined with melittin. In the present study, pure melittin was isolated from whole BV by flash chromatography to obtain pure melittin. The ability of melittin to enhance the release of tumour necrosis factor-α (TNF-α), Interleukin (IL-1β, IL-6, and IL-10) cytokines from a macrophage cell line (THP-1) was then assessed. The response to melittin and LPS, applied alone or in combination, was characterised by metabolic profiling, and the metabolomics results were used to evaluate the potential of melittin as an immune adjuvant therapy. The addition of melittin enhanced the release of inflammatory cytokines induced by LPS. Effective chromatographic separation of metabolites was obtained by liquid chromatography-mass spectrometry (LC-MS) using a ZIC-pHILIC column and an ACE C4 column. The levels of 108 polar and non-polar metabolites were significantly changed (p ˂ 0.05) following cell activation by the combination of LPS and melittin when compared to untreated control cells. Overall, the findings of this study suggested that melittin might have a potential application as a vaccine adjuvant.

AB - Melittin, the major active peptide of honeybee venom (BV), has potential for use in adjuvant immunotherapy. The immune system response to different stimuli depends on the secretion of different metabolites from macrophages. One potent stimulus is lipopolysaccharide (LPS), a component isolated from gram-negative bacteria, which induces the secretion of pro-inflammatory cytokines in macrophage cell cultures. This secretion is amplified when LPS is combined with melittin. In the present study, pure melittin was isolated from whole BV by flash chromatography to obtain pure melittin. The ability of melittin to enhance the release of tumour necrosis factor-α (TNF-α), Interleukin (IL-1β, IL-6, and IL-10) cytokines from a macrophage cell line (THP-1) was then assessed. The response to melittin and LPS, applied alone or in combination, was characterised by metabolic profiling, and the metabolomics results were used to evaluate the potential of melittin as an immune adjuvant therapy. The addition of melittin enhanced the release of inflammatory cytokines induced by LPS. Effective chromatographic separation of metabolites was obtained by liquid chromatography-mass spectrometry (LC-MS) using a ZIC-pHILIC column and an ACE C4 column. The levels of 108 polar and non-polar metabolites were significantly changed (p ˂ 0.05) following cell activation by the combination of LPS and melittin when compared to untreated control cells. Overall, the findings of this study suggested that melittin might have a potential application as a vaccine adjuvant.

KW - adjuvant vaccine

KW - LPS stimulation

KW - macrophages

KW - melittin

KW - PMA differentiated

KW - pro- and anti-inflammatory cytokines

KW - THP-1 cells

UR - http://www.scopus.com/inward/record.url?scp=85055849613&partnerID=8YFLogxK

UR - https://www.mdpi.com/journal/vaccines

U2 - 10.3390/vaccines6040072

DO - 10.3390/vaccines6040072

M3 - Article

VL - 6

JO - Vaccines

T2 - Vaccines

JF - Vaccines

SN - 2076-393X

IS - 4

M1 - 72

ER -